Long-Term Administration of Tianeptine in Depressed Patients after Alcohol Withdrawal

1992 ◽  
Vol 160 (S15) ◽  
pp. 66-71 ◽  
Author(s):  
R. Malka ◽  
H. Lôo ◽  
H. Ganry ◽  
A. Souche ◽  
C. Marey ◽  
...  
Keyword(s):  
Side Effects ◽  
Alcohol Withdrawal ◽  
Major Depressive Episode ◽  
Multicentre Trial ◽  
Dysthymic Disorder ◽  
Major Depressive ◽  
Depressed Patients ◽  
Term Administration ◽  
Neurochemical Effect

Alcohol interferes with the central metabolism of the catecholamines and especially with indolamines (5-HT). Thus, the use of an antidepressant such as tianeptine, whose main neurochemical effect is to increase the reuptake of 5-HT, seems to be particularly indicated for the continued treatment of depressed patients after alcohol withdrawal. This study evaluated the therapeutic efficacy and acceptability during long-term administration of tianeptine in depressed patients (major depressive episode or dysthymic disorder) in a multicentre trial, after withdrawal from alcohol abuse or dependence. The results relate to 130 depressed patients, who abstained from alcohol and received treatment for a year. Only one patient dropped-out because of side-effects, and medication was interrupted in 5% of subjects because of alcoholic relapses. Prescribed in the long term, tianeptine did not produce orthostatic hypotension, changes in bodyweight, or alterations in the ECG. All changes found in haematological and biochemical investigations suggested an improvement in patients' physical state. This, and other studies, indicate that tianeptine appears to have the potential to be a safe antidepressant, which might be particularly useful in those patients who are susceptible to the side-effects of psychotropic drugs.

Urinary monoamines and monoamine metabolites in subtypes of unipolar depressive disorder and normal controls

1986 ◽  
Vol 16 (3) ◽  
pp. 541-546 ◽  
Author(s):  
Alec Roy ◽  
David Pickar ◽  
Patrice Douillet ◽  
Farouk Karoum ◽  
Markku Linnoila
Keyword(s):  
Depressive Episode ◽  
Major Depressive Episode ◽  
Dysthymic Disorder ◽  
Monoamine Metabolites ◽  
Urinary Catecholamine ◽  
Major Depressive ◽  
Depressed Patients ◽  
Sympathetic Nervous ◽  
Normal Controls ◽  
Lower Urinary

SynopsisAn examination was made of urinary catecholamine and metabolite outputs in 28 unipolar depressed patients and 25 normal controls. The total group of depressed patients had significantly higher urinary outputs of norepinephrine (NE) and its metabolite normetanephrine (NM), and significantly lower urinary outputs of the dopamine metabolite dihydroxyphenylacetic acid (DOPAC), than controls. Patients who met DSM-III criteria for a major depressive episode with melancholia (N = 8) had significantly higher urinary outputs of normetanephrine than controls, whereas patients with a major depressive episode without melancholia (N = 7) and dysthymic disorder patients (N = 8) had levels comparable with controls. We postulate that the higher urinary outputs of norepinephrine and its metabolite, normetanephrine, reflect dysregulation of the sympathetic nervous system in depression.

Platelet counts in depressed patients treated with amitriptyline or paroxetine

2003 ◽  
Vol 18 (2) ◽  
pp. 89-91 ◽  
Author(s):  
F. Lederbogen ◽  
E. Hörer ◽  
R. Hellweg ◽  
I. Heuser ◽  
M. Deuschle
Keyword(s):  
Depressive Episode ◽  
Major Depressive Episode ◽  
Major Depressive ◽  
Thromboembolic Risk ◽  
Platelet Counts ◽  
Depressed Patients ◽  
Standardized Treatment ◽  
Dsm Iv

AbstractObjectiveTo assess whether therapy with two widely used antidepressants influences platelet counts.Subjects and methodsIn 90 patients hospitalized for treatment of a major depressive episode according to DSM-IV, platelet counts were performed after a 6 d antidepressant-free run-in period and again after 35 d of active standardized treatment with amitriptyline (n = 40) or paroxetine (n = 50).ResultsThere was a trend for platelet counts to increase during treatment with amitriptyline (from 245.5 ± 68.6 to 256.8 ± 69 cells × 109 L-1, P < 0.06); no change was observed during treatment with paroxetine (from 232.6 ± 58.3 to 234.6 ± 68.9 cells × 109 L-1, n.s).ConclusionsTreatment with amitriptyline tends to be associated with elevated platelet counts. The cause for this increase is not known, but may be relevant in terms of patients’ long-term thromboembolic risk.

scholarly journals A Review of the Treatment of Opioid-induced Constipation with Methylnaltrexone Bromide

2010 ◽  
Vol 2 ◽  
pp. CMT.S1168
Author(s):  
Francisco M. Abarca ◽  
Theodore J. Saclarides ◽  
Marc I. Brand
Keyword(s):  
Adverse Reaction ◽  
Side Effects ◽  
Severe Pain ◽  
Database Search ◽  
Mu Receptor ◽  
Quaternary Derivative ◽  
Term Administration ◽  
Data Source ◽  
Common Adverse Reaction

Objectives Review and summarize the mechanism of action of methylnaltrexone bromide (methylnaltrexone) and its effectiveness in the treatment of opioid-induced constipation. Data Source A multi-database search was conducted using PubMed and MEDLINE databases, in addition to electronic links to related articles and references. Background Opioids are effective medications for the management of moderate to severe pain, but they are associated with a number of side effects, especially within the gastrointestinal system. Constipation is a very common adverse reaction in patients with late-stage, adverse illness, who require long term administration of opioids on a chronic basis to help alleviate pain. In April 2008, the Food and Drug Administration approved the use of methylnaltrexone, a quaternary derivative of naltrexone which does not cross the blood brain barrier, for the management of patients with opioid-induced constipation. Methylnaltrexone acts as a selective peripheral Mu-receptor antagonist, without affecting the effects of opioids on central analgesia. Conclusions Studies have been shown that methylnaltrexone can be used safely in the treatment of opioid-induced constipation without either interfering with opioid effects on central anesthesia or precipitating opioid withdrawal.

scholarly journals Side-Effects of Long-Term Administration of Erlotinib in Patients with Non-small Cell Lung Cancer

2010 ◽  
Vol 5 (9) ◽  
pp. 1477-1480 ◽  
Author(s):  
Annemarie Becker ◽  
Atie van Wijk ◽  
Egbert F. Smit ◽  
Pieter E. Postmus
Keyword(s):  
Lung Cancer ◽  
Side Effects ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Term Administration

Responses to depression in unipolar depressed patients: an investigation of Nolen-Hoeksema's response styles theory

1999 ◽  
Vol 29 (6) ◽  
pp. 1323-1333 ◽  
Author(s):  
CHRISTINE KUEHNER ◽  
IRIS WEBER
Keyword(s):  
Gender Differences ◽  
Depressive Episode ◽  
Major Depressive Episode ◽  
Empirical Support ◽  
Response Styles ◽  
Post Discharge ◽  
Major Depressive ◽  
Depressed Patients ◽  
Response Styles Theory

Background. The response styles theory suggests that rumination in response to depressed mood exacerbates and prolongs depression, while distraction ameliorates and shortens it. Gender differences in response styles are said to contribute to the observed gender differences in the prevalence of unipolar depression. While empirical support for the theory has been found from a variety of non-clinical studies, its generalizability to clinically depressed patient populations remains unclear.Methods. A cohort of 52 unipolar depressed in-patients was assessed with the Response Styles Questionnaire during in-patient stay (T1) and 4 weeks after discharge (T2). The patients were followed up 4 months after discharge (T3). Clinical assessment included the SCAN-PSE-10.Results. Moderate and statistically significant retest-stabilities for rumination and distraction were found, comparable for patients with stable and changing depression status from T1 to T2. A cross-sectional diagnosis of a major depressive episode was associated with rumination, while gender was not. Post-discharge baseline rumination (T2), adjusted for concurrent depression, predicted follow-up levels of depression (T3), and, in patients who were non-remitted at post-discharge baseline, it predicted presence of a major depressive episode at follow-up (T3). Results on distraction were more ambiguous.Conclusions. Our results suggest that rumination is likely to have a deteriorating impact on the course of clinical episodes of depression in unipolar depressed patients. Larger longitudinal patient studies are needed to validate these findings.

Atypical antipsychotic drugs in dysthymia: placebo controlled studies of amisulpride versus imipramine, versus amineptine

1996 ◽  
Vol 11 (S3) ◽  
pp. 135s-140s ◽  
Author(s):  
P Boyer ◽  
Y Lecrubier
Keyword(s):  
Major Depressive Episode ◽  
Dysthymic Disorder ◽  
Therapeutic Effects ◽  
Major Depressive ◽  
Double Blind ◽  
Beneficial Effects ◽  
Intention To Treat ◽  
Point Analysis ◽  
Treat Analysis ◽  
Depressive Condition

SummaryIn order to assess the therapeutic efficacy of amisulpride in dysthymic disorder, two randomised double-blind trials were conducted in France. Both studies included outpatients meeting DSM-III-R criteria for primary dysthymia. Cases of double depressed patients with a mild or moderate major depressive episode superimposed to dysthymia were also eligible. The first study of a three-month duration compared amineptine (200 mg/day) to amisulpride (50 mg/day) and placebo. The second study of a six-month duration compared the therapeutic effects of imipramine (100 mg/day) to amisulpride (50 mg/day) and placebo. Results of the intention to treat analysis and of the end-point analysis were compelling and very similar: significant differences were demonstrated for all primary criteria between amisulpride and placebo and between imipramine and placebo but not between amisulpride and imipramine. For both primary criteria and the responder rate (CGI), statistically significant differences were evidenced between amisulpride and placebo and amineptine and placebo. The same differences were evidenced for SANS subscores. Beneficial effects of low doses of amisulpride in chronic depressive condition can therefore be discussed.

scholarly journals The Bluegreen Algae (AFA) Consumption over 48 h Increases the Total Number of Peripheral CD34+ Cells in Healthy Patients: Effect of Short-Term and Long-Term Nutritional Supplementation (Curcumin/AFA) on CD34+ Levels (Blood)

2020 ◽  
Vol 10 (2) ◽  
pp. 49
Author(s):  
José Joaquín Merino ◽  
María Eugenia Cabaña-Muñoz ◽  
María Jesús Pelaz
Keyword(s):  
Stem Cells ◽  
Side Effects ◽  
Healthy Subjects ◽  
Nutritional Supplementation ◽  
Double Blind Study ◽  
Short Term ◽  
Cd34 Cells ◽  
Term Administration ◽  
Bluegreen Algae

Several active principles from plants could trigger the release of stem cells from the bone marrow. Stem cell mobilizers have shown side effects in patients. Thus, the purpose of this paper is to find the natural products from plants (curcuminoids, glycosinolate of sulforaphane, AFA bluegreen algae), which could be potential stem mobilizes without adverse side effects. The antioxidant curcumin [1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-2,5-dione], glycosinolate of sulforaphane (broccoli) or AFA (Aphanizomenon flos) extract promote beneficial effects in patients. The number of circulating stem cells were monitored by HSC marker-CD34 by flow cytometry in peripheral blood from healthy subjects. CD34 is a hematological stem cells (HSC) marker. A double-blind study was conducted in 22 healthy subjects. We have evaluated whether short-term AFA—Aphanizomenon flos aquae—algae or curcuminoids consumption (powder or liquid formulation) over 48 consecutive hours could increase the total number of peripheral CD34+ blood cells (n = 22, n = 5 subjects/group). The total number of circulating CD34+ cells were quantified after short-term and long-term nutritional supplementation; their levels were compared with their own basal levels (n = 5/group, controls: before taking any supplement) or placebo-treated patients (n = 7); their average age was 54 years old. We also evaluated whether long-term nutritional supplementation with several nutraceuticals could enhance HSC mobilization by increasing the total number of peripheral CD-34+ cell after seven or 38 consecutive days of administration (n = 5, with seven placebo-treated patients). The long-term administration take place with these doses/day [curcuminoids: 2000 mg/day, equivalent to 120 mg of curcuminoids/day), glycosinolate of sulforaphane (66 mg/day), plus AFA Algae bluegreen extract (400 mg/day)]. On the last day (10 a.m.) of treatment, blood samples were collected six hours after taking these supplements; the average age was 54 years old. Notably, the blue green AFA algae extract consumption over 48 h enhances HSC mobilization by increasing the total number of peripheral CD34+ cells. The long-term administration with curcuminoids, glycosinolate of sulforaphane, and AFA bluegreen algae extract also increased the total number of CD34-HSC cells after seven or 38 days of consecutive of administration in healthy subjects.

Sign in / Sign up

Export Citation Format

Share Document